WB
H M R Mi
Endogenous
Rabbit
#P06730, #Q16539, #P04637, #P62753, #Q15418
1977, 1432, 7157, 6194, 6195
Product Information
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Mink
Source / Purification
Monoclonal antibodies are produced by immunizing animals with synthetic peptides. Polyclonal antibodies are produced by immunizing animals with synthetic peptides. Antibodies are purified by protein A and peptide affinity chromatography.
Product Description
Background
The 90 kDa ribosomal S6 kinases (RSK1-3) are a family of serine/threonine kinases broadly expressed in response to many growth factors, polypeptide hormones and neurotransmitters (1). p90RSK is activated by Erk1 and Erk2 in vitro and in vivo via phosphorylation (2). Several sites, such as Ser380, Thr359 and Ser363, are important for its activation (3).
The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (4). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (5,6). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to reduced interaction of p53 with its negative regulator, oncoprotein MDM2 (7).
p38 MAP kinase controls cellular responses to cytokines and stress (8-11). Like the SAPK/JNK pathway, p38 MAP kinase is activated by a variety of cellular stresses including osmotic shock, inflammatory cytokines, lipopolysaccharides (LPS), UV light and growth factors (8-12). MKK3, MKK6 and SEK activate p38 MAP kinase by phosphorylation at Thr180 and Tyr182.
Growth factors and mitogens induce the activation of p70 S6 kinase, which in turn phosphorylates the S6 ribosomal protein. Phosphorylation of S6 correlates with an increase in translation, particularly of mRNAs with an oligopyrimidine tract in their 5' untranslated regions (13). This group of mRNAs (5'TOP) encodes proteins involved in cell cycle progression and proteins that are part of the translational machinery, such as ribosomal proteins and elongation factors (13,14).
- Frodin, M. and Gammeltoft, S. (1999) Mol. Cell. Endocrinol. 151, 65-77.
- Lazar, D.F. et al. (1995) J. Biol. Chem. 270, 20801-20807.
- Dalby, K.N. et al. (1998) J. Biol. Chem. 273, 1496-1505.
- Levine, A.J. (1997) Cell 88, 323-331.
- Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
- Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
- Shieh, S.Y. et al. (1997) Cell 91, 325-334.
- Han, J. et al. (1994) Science 265, 808-811.
- Lee, J.C. et al. (1994) Nature 372, 739-746.
- Rouse, J. et al. (1994) Cell 78, 1027-1037.
- Freshney, N.W. et al. (1994) Cell 78, 1039-1049.
- Raingeaud, J. et al. (1995) J. Biol. Chem. 270, 7420-7426.
- Peterson, R.T. and Schreiber, S.L. (1998) Curr. Biol. 8, R248-R250.
- Jefferies, H.B. et al. (1997) EMBO J. 16, 3693-3704.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.